Pharmacokinetics, Pharmacodynamics, and Safety of a Human Anti-IL-6 Monoclonal Antibody (Sirukumab) in Healthy Subjects in a First-in-Human Study.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2011
At a glance
- Drugs Sirukumab (Primary)
- Indications Lupus nephritis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Apr 2011 New trial record